
Our story
2025

Q2 2025
- Earned a position in the 2025 MedTech Innovator Cohort

Q3 2025
- Kicked off pre-clinical testing campaign with strong results
2024

Q1 2024
- Prototype flow rate doubled
- Delivery profile decreased by 40%
- Second successful animal study

Q3 2024
-Closed a fully subscribed seed round
-2 additional U.S. patents were issued
2023

Q2 2023
- First fully functional prototype successfully delivered and operated in an animal

Q3-Q4 2023
- First 2 U.S. patents were issued
2022

Q1 2022
- Foundation of
Narwhal Medical

Q2 2022
- Initial prototypes created demonstrating concept potential

Q3 2022
- Major strategic partner joins Narwhal Medical to create functional
proof-of-concept prototypes

Stay Tuned For More Exciting Developments

Clinical Need
Loïc first observed the shortcomings of current percutaneous ventricular assist devices (pVADs) at a medical conference. He watched a challenging live case where the physicians were unable to deliver a pVAD through an axillary (shoulder) artery access site. Ultimately, the physician took a different treatment approach while also having to deal with closure of the axillary artery large bore access site in the middle of the procedure. Click here for more information about pVAD procedures.
​
We are creating a pVAD with the smallest delivery profile on the market. This will allow our blood pump to protect the lives of thousands of people every year who are ineligible for treatment with the current pVADs due to blood vessel size or blood vessel disease.